To page body
university of tampere: faculty of medicine and life sciences: research:
Faculty of Medicine and Life SciencesUniversity of TampereFaculty of Medicine and Life Sciences

Clinical Chemistry

Terho Lehtimäki
tel. +358 (0)50 433 6285

T Lehtimäki kuva pienempi.jpg

Terho Lehtimäki MD, PhD is currently a professor of Clinical Chemistry and Chief Physician of the Department of Clinical Chemistry, University of Tampere, Faculty of Medicine and Life Sciences and Fimlab Laboratories (Ltd), Pirkanmaa Hospital District, Finland which is the second largest clinical laboratory in Finland. His research interests are focused on cardiovascular disease risk factors, atherosclerosis biomarkers, vascular and cell biology and functional genetics of diseases. Terho Lehtimäki has over 800 publications from the field including articles in all world top journals, e.g., Science, Lancet, Nature, Nature Genetics, JAMA and Circulation. Tampere is a partner in several collaborative efforts within the European Union and in the US and Canada. In addition Terho Lehtimäki is the responsible investigator of the genetic section of The Cardiovascular Risk In Young Finns study (YFS) and The Finnish Cardiovascular Study (FINCAVAS) and the leader of The Tampere Vascular Study (TVS) focusing on the use of “OMICS” techniques in the research of atherosclerosis and functional genetics.

Terho Lehtimäki has skills in traditional and problem based teaching methods as part of the Faculty of Medicine and Life Sciences Tampere University which has been nominated three times as a Centre of Excellence in high level teaching by the Finnish Higher Education Evaluation Council. Professor Lehtimäki graduated as MD and PhD in 1992 from the University of Tampere. He was nominated as senior lecturer (docent) in Medical Biochemistry, at the University of Tampere in 1996, Specialist in Clinical Chemistry in 1999 and a senior lecturer (docent) in Clinical Chemistry, University of Kuopio in 2003. He has supervised over 50 thesis, master's thesis and medical advanced studies. Terho Lehtimäki has been involved in a national team of specialists since 2003 making national guidelines (Käypä hoito -suositus) for the prevention of dyslipidemias and cardiovascular diseases. Also, Terho Lehtimäki is a member of the board of the Finnish Medical Association of Clinical Chemistry and member of the editorial board in two international journals. Terho Lehtimäki’s research group is well recognized and represented in over 35 international consortia.


Emma Raitoharju, Leo-Pekka Lyytikäinen, Nina Mononen, Niku Oksala, Ilkka Seppälä, Tuukka Taipale, Miska Sulkava, Ismo Hänninen, Juho-Pekka Karjalainen, Jaakko Laaksonen, Leena Hakkarainen, Pashupati Mishra, Kati Sundström, Sari Tuomisto, Antti Blankenstein

Research Assistants:

Tiina Ceder, Ulla Kala (sijaisena Kati Hakala)

Ongoing research projects:

Genetic and biochemical factors predisposing to atherosclerosis

Lehtimäki and his team study atherosclerosis, the metabolism associated with cardiovascular diseases and the biology of the blood vessel wall. One of the most important study lines currently are the genetics and epigenetic studies of complex diseases and traits, including cardiovascular risk factors and diseases. The concept of “vulnerable plaque” has been extended to the more recent definition of the “cardiovascular vulnerable patient,” in which “intraplaque” and “systemic” factors contribute to the cumulative risk of acute cardiovascular events. The traditional view that atherosclerosis is simply a lipid storage disease has been challenged by a growing body of evidence of other key components contributing to the disease etiology, like inflammation pathways that play a central role in all stages of atherosclerotic disease from the early initial lesion to the late-stage plaque rupture. However, molecular mechanisms promoting premature atherosclerosis development and plaque rapture are not fully understood and this has severely hampered the advance of diagnostic and therapeutic programs. One of the major problems in clinical practice is to recognize a high risk unstable plaque carrying patient. Also, no current therapeutic regime directly targets atherosclerosis. The present study plan is a continuation of the 5-year AtheroRemo Project (2008-2013), funded by The European Union 7th Framework Program. AtheroRemo has been originally designed to advance the present knowledge on the role of inflammatory remodeling in the different stages of atherosclerosis.



Terkko Scholar Chart >> Fimlab Laboratoriot Oy >>
PubMed >> Terho Lehtimäki's citations >>
Young Finns Study >>
AtheroRemo >> Science Prize >>
Maintained by:
Last update: 8.5.2018 12.55 Muokkaa

University of Tampere
+358 3 355 111

FINEEC Audited HR Excellence in Research

Cooperation and Services
About Us

Research & Study

Career Services
Finnish Social Science Data Archive
Centre for International Education
IT services
Language Centre
Language Services
Registrar's Office
Sports Activities
» more

Teaching schedules
Curricula guides
Student's Desktop

Andor search
Renew your loans
UTA intranet
Office 365 webmail
Uta webmail
Electronic exam service
Examination results